150 related articles for article (PubMed ID: 37933640)
1. [High expression of secretogranin II increases oxaliplatin resistance of colorectal cancer cells].
Deng J; Pan T; Zhou G; Gao Y; Peng W; Wei W; Lü C
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Oct; 43(10):1657-1664. PubMed ID: 37933640
[TBL] [Abstract][Full Text] [Related]
2. Secretogranin II impairs tumor growth and angiogenesis by promoting degradation of hypoxia-inducible factor-1α in colorectal cancer.
Fang C; Dai L; Wang C; Fan C; Yu Y; Yang L; Deng H; Zhou Z
Mol Oncol; 2021 Dec; 15(12):3513-3526. PubMed ID: 34160138
[TBL] [Abstract][Full Text] [Related]
3. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
[TBL] [Abstract][Full Text] [Related]
4. SCG2 is a Prognostic Biomarker Associated With Immune Infiltration and Macrophage Polarization in Colorectal Cancer.
Wang H; Yin J; Hong Y; Ren A; Wang H; Li M; Zhao Q; Jiang C; Liu L
Front Cell Dev Biol; 2021; 9():795133. PubMed ID: 35047505
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
[TBL] [Abstract][Full Text] [Related]
6. EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer.
Xiao Z; Liu Y; Li Q; Liu Q; Liu Y; Luo Y; Wei S
Cancer Chemother Pharmacol; 2021 Dec; 88(6):1021-1031. PubMed ID: 34599680
[TBL] [Abstract][Full Text] [Related]
7. Prostaglandin F
Wang YJ; Xie XL; Liu HQ; Tian H; Jiang XY; Zhang JN; Chen SX; Liu T; Wang SL; Zhou X; Jin XX; Liu SM; Jiang HQ
World J Gastroenterol; 2023 Oct; 29(39):5452-5470. PubMed ID: 37900995
[TBL] [Abstract][Full Text] [Related]
8. Casein Kinase 2α Augments Oxaliplatin Resistance in Colorectal Cancer Cells by Increasing ABCE1 Expression.
Yun CW; Lee JH; Lee SH
Anticancer Res; 2023 Jun; 43(6):2519-2525. PubMed ID: 37247928
[TBL] [Abstract][Full Text] [Related]
9. Intense endoplasmic reticulum stress (ERS) / IRE1α enhanced Oxaliplatin efficacy by decreased ABCC10 in colorectal cancer cells.
Liu X; Wu B; Chen H; Sun H; Guo X; Sun T; Zhou D; Yang S
BMC Cancer; 2022 Dec; 22(1):1369. PubMed ID: 36585626
[TBL] [Abstract][Full Text] [Related]
10. SCG2: A Prognostic Marker That Pinpoints Chemotherapy and Immunotherapy in Colorectal Cancer.
Weng S; Liu Z; Ren X; Xu H; Ge X; Ren Y; Zhang Y; Dang Q; Liu L; Guo C; Beatson R; Deng J; Han X
Front Immunol; 2022; 13():873871. PubMed ID: 35844556
[TBL] [Abstract][Full Text] [Related]
11. Tumor suppressor circPDE4D inhibits the progression of colorectal cancer and regulates oxaliplatin chemoresistance.
Li J; Lv J; Chen Y; Li L
Gene; 2023 May; 864():147323. PubMed ID: 36858188
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Girdin enhances chemosensitivity of colorectal cancer cells to oxaliplatin.
Zhang YJ; Li AJ; Han Y; Yin L; Lin MB
World J Gastroenterol; 2014 Jul; 20(25):8229-36. PubMed ID: 25009397
[TBL] [Abstract][Full Text] [Related]
13. miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity.
Hua Y; Zhu Y; Zhang J; Zhu Z; Ning Z; Chen H; Liu L; Chen Z; Meng Z
Cell Physiol Biochem; 2018; 51(5):2148-2159. PubMed ID: 30522111
[TBL] [Abstract][Full Text] [Related]
14. Differential Reovirus-Specific and Herpesvirus-Specific Activator Protein 1 Activation of Secretogranin II Leads to Altered Virus Secretion.
Berard AR; Severini A; Coombs KM
J Virol; 2015 Dec; 89(23):11954-64. PubMed ID: 26378181
[TBL] [Abstract][Full Text] [Related]
15. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
Fang Z; Gong C; Yu S; Zhou W; Hassan W; Li H; Wang X; Hu Y; Gu K; Chen X; Hong B; Bao Y; Chen X; Zhang X; Liu H
Cancer Lett; 2018 Feb; 415():58-72. PubMed ID: 29203250
[TBL] [Abstract][Full Text] [Related]
16. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637.
Zhang Y; Li C; Liu X; Wang Y; Zhao R; Yang Y; Zheng X; Zhang Y; Zhang X
EBioMedicine; 2019 Oct; 48():277-288. PubMed ID: 31631038
[TBL] [Abstract][Full Text] [Related]
17. Secretogranin II binds to secretogranin III and forms secretory granules with orexin, neuropeptide Y, and POMC.
Hotta K; Hosaka M; Tanabe A; Takeuchi T
J Endocrinol; 2009 Jul; 202(1):111-21. PubMed ID: 19357184
[TBL] [Abstract][Full Text] [Related]
18. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
[TBL] [Abstract][Full Text] [Related]
19. A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer.
Madigan JP; Robey RW; Poprawski JE; Huang H; Clarke CJ; Gottesman MM; Cabot MC; Rosenberg DW
Exp Cell Res; 2020 Mar; 388(2):111860. PubMed ID: 31972222
[TBL] [Abstract][Full Text] [Related]
20. Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice.
Li X; Xia L; Ouyang X; Suyila Q; Su L; Su X
Protein Pept Lett; 2019; 26(7):512-522. PubMed ID: 30950338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
